

ISPOR Europe 2025

9-12 November 2025

Glasgow, Scotland

Meet Fortrea's Market Access Consulting & HEOR team at ISPOR Europe 2025

Stop by one of our nine posters to see examples of our work in market access strategy, health economic modeling and RWD analysis.

10 NOVEMBER | POSTER SESSION 1 | 10:30 - 13:30

Comparative Health Economic Evaluation of Alzheimer's Diagnostic Treatment Strategies in the Era of Amyloid-Targeting Therapies: A Conceptual Model Framework [EE140]

Arturo Cabra, BS, MSc¹, Montserrat Chivite, MSc², Gill Farrar, PhD³, Emilija Veljanoska, MSc⁴, Anna Tokarz, MSc⁴, Sofia Gomes, PharmD⁴, Agota Szende, PhD⁴.

Health Utilities Among Patients with Chronic Rhinosinusitis with Nasal Polyps: An Exploratory Analysis from the WAYPOINT Trial [EE495]

Danny Gibson, MASC⁵, Agota Szende, PhD⁴, Emilija Veljanoska, MSc⁴, Sam Colman, MBios⁴, Santiago Zuluaga Sanchez, MSc⁶.

A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies [HPR5]

Christianna Pepingco, MPH⁴, António Cardoso, MSc⁴, Kathryn Plante, MS⁴.

10 NOVEMBER | POSTER SESSION 2 | 16:00 - 19:00

Digital Therapeutics in Europe: A Structured Review Of Reimbursement and Access Pathways [MT14]

Ruth Zeidman, PhD⁷, Solene Bimbenet, PharmD⁸, Sofia Gomes, PharmD⁴, Alison Howell, PhD⁴.

11 NOVEMBER | POSTER SESSION 4 | 16:00 - 19:00

Exploring LLMs in the Conceptual and Functional Construction of Health Economic Models: A Case Study on Alzheimer's Diagnostic Cost-Effectiveness Model [EE457]

Emilija Veljanoska, MSc⁴, Agota Szende, PhD⁴.

Trends, Regulatory Landscape and Challenges in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review [HPR173]

António Cardoso, MSc⁴, Matthew Wallace, MPharm, MPH⁴.

Healthcare Resource Use Among Patients with Chronic Rhinosinusitis with Nasal Polyps in the United Kingdom: Results of an Expert Elicitation Survey [EE503]

Danny Gibson, MASC⁵, Santiago Zuluaga Sanchez, MSc⁶, Matthew Wallace, MPharm, MPH⁴, Emilija Veljanoska, MSc⁴, Agota Szende, PhD⁴.

11 NOVEMBER | POSTER SESSION 5 | 9:00 - 11:30

Technical validation of health economic models – is there a gold standard? Assessment and refinement of current checklist tools [EE684]

Anna Tokarz, MSc⁴, Agota Szende, PhD⁴.

Impact of Anosmia Severity on Health Utility Values in Chronic Rhinosinusitis with Nasal Polyps: An Exploratory Analysis from the WAYPOINT Trial [EE525]

Danny Gibson, MASC⁵, Sam Colman, MBios⁴, Agota Szende, PhD⁴, Santiago Zuluaga Sanchez, MSc⁶.



Scan the QR code for more information

¹GE HealthCare, Miami, FL, USA; ²GE Healthcare, Madrid, Spain; ³GE Healthcare, Little Chalfont, United Kingdom; ⁴Market Access Consulting & HEOR, Fortrea; ⁵Market Access and Pricing, AstraZeneca, Cambridge, United Kingdom; ⁶Health Economics, Amgen, Uxbridge, United Kingdom; ⁷Viatis, Hatfield, United Kingdom; ⁸Viatis, Zug, Switzerland